Companies
1cell.ai
OncoIndx / OncoTarget / Prime Plus — Multi-omic oncology product suite.
- Country
- India
Growth
OncoIndx / OncoTarget / Prime Plus
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $16 million Series A raised on November 22, 2024 | inc42.com · techcrunch.com |
| Certification | CAP accredited, CLIA certified, NABL accredited, and ISO certified lab | 1cell.ai |
| Headcount | approximately 174-191 employees as of 2026 | techcrunch.com |
| Revenue | ₹41.9 crore (approx. $5M USD) for the financial year ending March 31, 2025 | inc42.com |
| Production site | Pune, India | techcrunch.com |
Independent sources: inc42.com · techcrunch.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-omics diagnostic panels for precision oncology | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.